A chronic lung infection with Pseudomonas aeruginosa is associated with an increased exacerbation and mortality rate in people affected by bronchiectasis. Inhaled antibiotics are frequently used in clinical practice to treat chronic infections with this bacterium. The PROMIS-I and PROMIS-II studies investigated the efficacy and safety of 12-month inhaled colistimethate sodium administration in patients with bronchiectasis and chronic P. aeruginosa infection.
Autoren
- Jens Dehn
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
Related Topics
You May Also Like
- Pelargonium sidoides
Scoping review sheds light on the multifaceted spectrum of effects
- New evidence on genetics, pathophysiology and clinical significance
Migraine with and without aura – two different entities?
- Prevention of skin cancer
UV protection and skin cancer screening – Update 2025
- Case report: L. pneumophila pneumonia
Negative test results – but no alternative diagnoses
- Clinical case reports and implications for GP care
Magnesium deficiency and dilated cardiomyopathy in the peripartum context
- SID Annual Meeting: Highlights
Update on inflammatory dermatoses – a concentrated load of innovative power
- Case series
Bleeding prophylaxis for von Willebrand disease
- A critical analysis of the evidence from 113 studies